Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
as soon as is submitted to ZB.
One small molecule for man, one giant leap for mankind with obesity.
Med. 6:100924 (2025)
The ATTAIN-1 trial launches a new era in obesity care. Orforglipron, the first oral small-molecule GLP-1 receptor agonist to complete a phase 3 clinical trial, delivers meaningful reductions in body weight and improvements in metabolic health. This advancement moves beyond peptide-based injectables, paving the way for potent obesity therapies that are simpler, more affordable, and accessible to millions worldwide.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Editorial
ISSN (print) / ISBN
2666-6359
e-ISSN
2666-6340
Journal
Med (N Y)
Quellenangaben
Volume: 6,
Issue: 12,
Article Number: 100924
Publisher
Cell Press
Reviewing status
Peer reviewed
Institute(s)
Institute of Diabetes and Obesity (IDO)